Targeting B-cell Maturation Antigen in Relapsed/Refractory Multiple Myeloma: New Findings in Clinical Context

Please Log In or Register to continue.

Release Date: December 04, 2019
Expiration Date: December 04, 2020

Expected time to complete this activity as designed: 120 minutes
There are no fees for participating in or receiving credit for this online activity.

This activity was previously presented on September 6, 2019 to a live audience during the ASH Meeting on Hematologic Malignancies in Chicago, Illinois. Please note: If you attended the live meeting or simulcast viewing, you are ineligible to receive an additional 2.0 contact hours of credit and may not re-submit for credit previously awarded.

Program Overview

Awareness and knowledge of B-cell maturation antigen (BCMA) as a therapeutic target remains limited among clinicians who provide care for patients with relapsed/refractory multiple myeloma (MM). However, the number of clinical trials evaluating these therapies is rapidly increasing; and a few have even received breakthrough therapy status. In this activity, three myeloma experts discuss the most recent and up-to-date clinical trial information on this exciting topic. Hear what is to come in the near future and how these emerging agents will be positioned in the treatment of relapsed multiple myeloma.

Goals

  • Learners will demonstrate increased awareness and knowledge of key concepts in BCMA targeting, including the role of BCMA as a marker of disease, pathogenesis, and prognosis (Knowledge, Competence)
  • Learners will have increased confidence and knowledge in the current state of BCMA-directed therapy, including working knowledge of efficacy data from clinical trials and of breakthrough status designations for specific therapies (Knowledge, Competence)
  • Learners will be better prepared for eventual management of side effects characteristic of specific BCMA-directed therapies (Knowledge)

Target Audience

This activity is designed for multidisciplinary healthcare providers in the community setting, including oncologists/hematologists, nurses, pharmacists and other healthcare professionals who provide care to patients with multiple myeloma.

Educational Methods

Lecture/Didactic, Audience Response System, Panel discussion, Pre-/Post-Test, Question/Answer Sessions

Educational Objectives

At the conclusion of this educational activity, the participant should be able to:

  • Explain the importance of BCMA as a therapeutic target in multiple myeloma as shown in studies of antibody-drug conjugates, T-cell based therapy, and other approaches (Knowledge, Competence)
  • Describe how BCMA-directed therapy may fit into clinical practice for multiple myeloma given the results of recently published clinical studies (Knowledge, Competence)
  • Discuss how toxicities of BCMA-targeted therapies are optimally managed based on established practices and emerging investigations (Knowledge)

Agenda

BCMA as a Target of Therapy: Rapidly Emerging Opportunities – Nikhil C. Munshi, MD

BCMA-Directed Therapy – Efficacy Results and Interactive Case Study: Use of BCMA-Directed Treatment in Clinical Trials – Robert Z. Orlowski, MD, PhD

Safety of BCMA-Directed Therapy and Interactive Case Study: Use of BCMA-Directed Therapy in Light of Safety and Efficacy – Nina Shah, MD

Instructions for Participation and Credit

This activity is eligible for credit through December 4, 2020. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates for CME and CNE may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biographies

Robert Z. Orlowski, MD, PhD
Professor, Chair Ad Interim
Department of Lymphoma/Myeloma
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Dr. Robert Orlowski earned his doctoral degree in molecular biophysics and biochemistry from Yale University and his medical degree from the Yale University School of Medicine. He completed his internship and residency in internal medicine at Barnes Hospital at Washington University, St. Louis School of Medicine. Dr. Orlowski is a Professor and Chair Ad Interim in the Department of Lymphoma/Myeloma, and Professor in the Department of Experimental Therapeutics, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center.

Board-certified in internal medicine and medical oncology, Dr. Orlowski has published numerous book chapters, articles, and abstracts on cancer therapy with a focus on the pathogenesis of oncologic disease and mechanisms of action of chemotherapeutics. In addition, he is a reviewer for several journals, including Blood, Cancer Research, Journal of Clinical Oncology, and The New England Journal of Medicine. His clinical research efforts focus on novel clinical trials for patients with hematologic malignancies.

Nikhil C. Munshi, MD
Professor of Medicine
Harvard Medical School
Associate Professor, Medical Oncology
Dana-Farber Cancer Institute
Boston, Massachusetts

Dr. Nikhil Munshi received his medical degree from Maharaja Sayajirao University and Shri Sayaji General Hospital in Baroda, India. He completed a medical oncology research fellowship at Johns Hopkins Oncology Center before receiving a clinical fellowship in hematology/oncology at Indiana University Medical Center. Dr. Munshi is Professor of Medicine at Harvard Medical School, the Director of Basic and Correlative Science, and Associate Director of the Jerome Lipper Multiple Myeloma Center at the Dana Farber Cancer Institute. In addition, he is an attending physician at the Brigham and Women’s Hospital and the Boston VA Healthcare System, Harvard Medical School.

Dr. Munshi has organized and chaired numerous guideline panels to develop consensus recommendations for management of myeloma. He serves as a co-chair of the National Steering Committee on Myeloma (National Cancer Institute), is member of the National Cancer Institute Clinical Trials and Translational Research Advisory Committee, and is a founding member and vice-president of the International Myeloma Society. Dr. Munshi has written more than 400 peer-reviewed publications and has contributed chapters on plasma cell neoplasms in Harrison’s Principles of Internal Medicine; DeVita’s Principles and Practice of Oncology, and Hoffman’s Hematology: Basic Principles and Practice. He received a Leukemia Society of America Scholar in Translational Research and the Waldenström’s Award for the most Distinguished Lifetime Achievement in Myeloma Research in 2013.

A recognized international leader in translational research in multiple myeloma, Dr. Munshi’s focus spans both basic sciences to understand molecular mechanisms driving the genomic instability to translational approaches directed at improving diagnosis and prognosis, as well as therapeutics including novel antigen-directed immunotherapy/vaccine approaches and small molecules for myeloma. His research has provided pivotal understanding of genomic changes in myeloma.

Nina Shah, MD 
Associate Professor
Hematology-Oncology 
University of California San Francisco
San Francisco, California

Dr. Nina Shah is an Associate Professor in the Division of Hematology-Oncology at University of California San Francisco. Her research focuses on multiple myeloma, specifically immunotherapy and cellular therapy. Dr. Shah performed the first-in-human clinical trial of umbilical cord blood-derived natural killer cell therapy for myeloma and is currently one of the three lead principal investigators (PI) for the multi-center BMT CTN 1401 dendritic cell vaccine trial for myeloma patients. In addition, she is involved in numerous CAR-T and immunotherapy protocols.

Dr. Shah is also interested in outcomes research for myeloma patients undergoing autologous transplantation, she has led a randomized trial to determine the impact of stem cell dose on symptoms in this patient population and has also published on patient reported outcomes in this clinical context. Dr. Shah is heavily involved in the myeloma research community and led the effort to define myeloma-transplant practice guidelines for the American Society of Blood and Marrow Transplant (ASBMT). She serves as a co-chair for the Plasma Cell Disorders and Adult Solid Tumors Working Committee at the Center for International Blood & Marrow Transplant Research (CIBMTR).

Accreditation/Credit Designation

MD Anderson Cancer Center CME CREDIT
The University of Texas MD Anderson Cancer Center is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Texas MD Anderson Cancer Center designates this enduring activity for a maximum of 2.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ACPE CPE CREDIT
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 2.0 contact hours of Continuing Education Credit.
Universal Activity Number: 827-0000-19-021-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.

MediCom Worldwide, Inc. NURSING CREDIT
Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 2.0 contact hours. Program Number: 19-021-110

CME Certificates and Attendance Certificates

Certificates awarding AMA PRA Category 1 Credit™ or certificates documenting participation will be issued immediately to participants when an individual completes the post-test and evaluation.

Non-Physicians will receive a certificate of participation in accordance with state nursing boards, specialty societies, or other professional associations.


The University of Texas MD Anderson Cancer Center Disclosure Policy for Program Chairs, Planning Committee Members, Teachers, or Authors and CME Activity Reviewers

The Accreditation Council for Continuing Medical Education has announced standards and guidelines to insure that individuals participating in CME activities are aware of program chair(s), planning committee members, faculty/teacher/ authors, CME activity reviewer’s relationships with commercial interests that could potentially affect the information presented. The University of Texas MD Anderson Cancer Center has implemented a process whereby everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships with any commercial interest.

The University of Texas MD Anderson Cancer Center has, through a formal review process, resolved all conflicts of interest prior to this activity. For information on this process, please contact CME/Conference Management at (713) 792-5357.

The following Faculty, Program Planning Committee Members and CME Activity Reviewers/Approvers have financial interests, arrangements or affiliations with the manufacturer of any product or devices to be discussed, or who may financially support this CME activity, as indicated below. An asterisk (*) indicates that the faculty’s presentation will include discussion of investigational or off-label uses of a product.

FACULTY

COMMERCIAL INTEREST

Nikhil Munshi, MD

Paid consultant: Abbive, Adapative, Amgen, Celgene, Janssen, Takeda, Oncopep;
Ownership interest: Oncopep

Robert Z. Orlowski, MD, PhD*

Grant or research support:  Amgen, BioTheryX, Spectrum Pharmaceuticals
Membership advisory board: Amgen, Bristol-Myers Squibb, Celgene, Janssen, Kite Pharmaceuticals, Sanofi-Aventis, Takeda

Nina Shah, MD*

Grant or research support: Celgene, Janssen, Bluebird Bio, Sutro
Paid consultant: Genentech, Seattle Genetics, Oncopeptides, Karyopharm, Surface Oncology, Precision Biosciences, GlaxoSmithKline, Nektar, Amgen, Indapta Therapeutics, Sanofi
Ownership interest: Indapta

PLANNING COMMITTEE MEMBERS

COMMERCIAL INTEREST

Robert Z. Orlowski, MD, PhD

Grant or research support:  Amgen, BioTheryX, Spectrum Pharmaceuticals
Membership advisory board: Amgen, Bristol-Myers Squibb, Celgene, Janssen, Kite Pharmaceuticals, Sanofi-Aventis, Takeda


The following Faculty/Program Planning Committee Members and CME Activity Reviewers/Approvers HAVE INDICATED THEY HAVE NO FINANCIAL INTERESTS, arrangements or affiliations with the manufacturer of any product or devices to be discussed, or who may financial support this CME activity. An asterisk (*) indicates that the faculty’s presentation will include discussion of investigational or off-label uses of a product.

PLANNING COMMITTEE MEMBERS

Tamara Greiner

Joan Meyer, RN, MHA

Andrea Mathis

Bill Stoff

CME ACTIVITY REVIEWERS/APPROVERS

Diane C. Bodurka, MD, BS, MPH (approver)

Aurelio Matamoros Jr., MD

Bruno Granwehr, MD

Teresa Moon, MD



CPE, CNE Disclosure

As an organization accredited by the Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest that could potentially affect the information presented. Accordingly, the following disclosures were made.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at lisa@medicaled.com

Provided by The University of Texas MD Anderson Cancer Center and MediCom Worldwide, Inc.
This activity is supported by educational grants from Celgene Corporation and GlaxoSmithKline.

©2019 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

Please Log In or Register to continue.